Cerevance

Big milestone: We’ve fully enrolled 341 patients in the Phase 3 ARISE trial of solengepras—a potential first-in-class, non-dopaminergic therapy for Parkinson's—and closed a $20M Series C to fund us through topline data this year. bit.ly/3Pd7IcS #Biotech #ClinicalTrials

We’re inspired by the vibrant scientific exchange across the neurology community at #AANAM. Phase 2 solengepras data, presented by Drs. Sarva and Hauser, showed meaningful reductions in OFF time and improvement in sleep-related symptoms in #PD. Learn more: bit.ly/41MiFoq

OFF time. Sleep disturbance. Daily unpredictability. Phase 2 solengepras data showed the potential impact of targeting GPR6 to address these non-motor outcomes, marking a shift in how we treat #PD. Phase 3 results are coming later this year. Learn more: bit.ly/48aJOF3

We’re heading to #AANAM to present Phase 2 data for solengepras showing reductions in OFF time and improvements in sleep in #Parkinsons disease. Learn about our presentations: bit.ly/3PYWybJ

We’re presenting new Phase 2 data for solengepras, our investigational oral GRP6 inhibitor, at #ADPD2026 in Copenhagen. Learn how our science aims to expand treatment options: bit.ly/4dd8pwc

Our Parkinson’s research is grounded in science and strengthened by partnerships. We were proud to stand with the PD community at the MJFF Los Angeles Run/Walk, united by a shared commitment to advancing progress in PD. Get involved with @MichaelJFoxOrg: bit.ly/4shp1XQ

We’re excited to connect with the neuroscience community at the TD Cowen 46th Annual Health Care Conference in Boston next week, where our leadership team will meet with investors to share updates on our latest research in neurodegenerative diseases: bit.ly/40pdxpr

At Cerevance, we’re aiming to provide a new treatment option for individuals with #PD that shifts beyond dopamine, offering an entirely differentiated mechanism of action that can better improve daily life experiences. Read about it in @FierceBiotech: bit.ly/3MN2v9O

We’re excited to present new data from our Phase 2 adjunctive study of solengepras at the #PSG2025 Annual Meeting today. Discover how solengepras demonstrated significant reductions in OFF time in individuals with #Parkinsons disease: bit.ly/3YbpJZL

Advancing Parkinson’s care with a novel, non-dopaminergic approach. Next week at the PSG Annual Meeting in San Diego, we’re excited to showcase solgenepras and its potential to address unmet needs in Parkinson’s disease. Learn about our presentations: bit.ly/4olH2lD

We’re excited to share our latest research in obesity and neurodegenerative disorders driven by #neuroinflammation at the upcoming TD Cowen Treatment Advancements in Obesity and Related Disorders Summit. Learn about our panel discussion: bit.ly/3XwC2zs

We had a great time connecting with the global movement disorders community at last week’s #MDSCongress, where we presented findings from our Phase 2 ASCEND trial of solengepras. Learn more about how we’re driving innovation in #PD research: bit.ly/3J6u7oZ

Curious how our proprietary NETSseq platform is advancing drug discovery for #neurodegenerative disorders? Hear from our CEO, Craig Thompson, as he discusses our unique research capabilities with @PharmExec: bit.ly/478dzGj

Join us at the 2025 #MDSCongress in Honolulu, where we’ll present the promising findings from our Phase 2 ASCEND trial of solengepras in patients with early, untreated #PD. Learn more about our oral presentation: bit.ly/3ICx14F We hope to see you there!

Our global Phase 3 ARISE trial represents an important step in our efforts to drive progress in #Parkinsons research and better serve the needs of individuals living with #PD. Learn more: bit.ly/45EGos5

On #WorldBrainDay, we highlight our commitment to advancing the understanding of neurological disorders, including #Parkinsons disease. Our Phase 3 ARISE trial represents a pivotal step in this mission. Learn more: bit.ly/4eYQubH

Our CEO, Craig Thompson, looks forward to presenting our latest research in Alzheimer’s and other #neurodegenerative diseases driven by neuroinflammation at #AAIC25 later this month. Check out our posters: bit.ly/3TGaTbC

Living with #PD can be daunting, but every day, new strides in research bring us closer to advancing novel treatment options for this community. Learn about our Phase 3 ARISE trial of solengepras in #PD and see if you qualify for enrollment: bit.ly/4etuXaM

Our CEO, Craig Thompson, was at #BIO2025 last week, where he engaged in valuable discussions with leaders in the biotech community that will continue to inspire our efforts to tackle #CNS disorders. Learn more about our ongoing research: bit.ly/4eeWGvP

Dr. Stuart Isaacson recently participated in a discussion with @VJNeurology, highlighting how our clinical research could potentially provide a differentiated approach to the treatment of #PD. Check it out: bit.ly/3ZtDBzL